These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 32298020)

  • 41. Marked telomere shortening in mobilized peripheral blood progenitor cells (PBPC) following two tightly spaced high-dose chemotherapy courses with G-CSF.
    Ricca I; Compagno M; Ladetto M; Rocci A; Dell'Aquila M; Omedè P; De Marco F; D'Antico S; Caracciolo D; Ferrero D; Carlo-Stella C; Tarella C
    Leukemia; 2005 Apr; 19(4):644-51. PubMed ID: 15716989
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Stem cell mobilization in multiple myeloma patients relapsing after previous autologous hematopoietic stem cell transplantation: A multicenter report by the Polish Myeloma Study Group.
    Drozd-Sokołowska J; Waszczuk-Gajda A; Topczewska M; Mańko J; Hus I; Szmigielska-Kapłon A; Nowicki M; Grygoruk-Wiśniowska I; Krawczyk-Kuliś M; Romejko-Jarosińska J; Frączak E; Wróbel T; Piątkowska-Jakubas B; Mądry K; Boguradzki P; Król M; Kozioł M; Hus M; Kopińska A; Dmoszyńska A; Basak GW; Dwilewicz-Trojaczek J
    J Clin Apher; 2021 Jun; 36(3):443-453. PubMed ID: 33592119
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Increased efficacy of intermediate-dose cytarabine + G-CSF compared to DHAP + G-CSF for stem cell mobilization in patients with lymphoma: an analysis by the polish lymphoma research group.
    Giebel S; Sadus-Wojciechowska M; Halaburda K; Drozd-Sokolowska J; Wierzbowska A; Najda J; Mendrek W; Sobczyk-Kruszelnicka M; Nowicki M; Holowiecki J; Czerw T
    Ann Hematol; 2016 Jan; 95(2):263-9. PubMed ID: 26611854
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Successful hematopoietic stem cell collection in patients who fail initial plerixafor mobilization for autologous stem cell transplant.
    Veeraputhiran M; Jain T; Cronin S; Al-Kadhimi Z; Abidi MH; Ayash L; Mellert K; Lum LG; Ratanatharathorn V; Uberti JP; Deol A
    J Clin Apher; 2014 Dec; 29(6):293-8. PubMed ID: 24700728
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma.
    Demirer T; Buckner CD; Gooley T; Appelbaum FR; Rowley S; Chauncey T; Lilleby K; Storb R; Bensinger WI
    Bone Marrow Transplant; 1996 Jun; 17(6):937-41. PubMed ID: 8807097
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.
    Lor KW; Helmons PJ; Belew H; Lane JR; Ball ED
    Pharmacotherapy; 2012 Jul; 32(7):596-603. PubMed ID: 22760691
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of chemotherapy regimen and hematopoietic growth factor on mobilization and collection of peripheral blood stem cells in cancer patients.
    Nowrousian MR; Waschke S; Bojko P; Welt A; Schuett P; Ebeling P; Flasshove M; Moritz T; Schuette J; Seeber S
    Ann Oncol; 2003; 14 Suppl 1():i29-36. PubMed ID: 12736228
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF.
    Koç ON; Gerson SL; Cooper BW; Laughlin M; Meyerson H; Kutteh L; Fox RM; Szekely EM; Tainer N; Lazarus HM
    J Clin Oncol; 2000 May; 18(9):1824-30. PubMed ID: 10784622
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide.
    Shaughnessy P; Islas-Ohlmayer M; Murphy J; Hougham M; MacPherson J; Winkler K; Silva M; Steinberg M; Matous J; Selvey S; Maris M; McSweeney PA
    Biol Blood Marrow Transplant; 2011 May; 17(5):729-36. PubMed ID: 20813198
    [TBL] [Abstract][Full Text] [Related]  

  • 50. G-CSF plus preemptive plerixafor vs hyperfractionated CY plus G-CSF for autologous stem cell mobilization in multiple myeloma: effectiveness, safety and cost analysis.
    Antar A; Otrock ZK; Kharfan-Dabaja MA; Ghaddara HA; Kreidieh N; Mahfouz R; Bazarbachi A
    Bone Marrow Transplant; 2015 Jun; 50(6):813-7. PubMed ID: 25751646
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
    Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
    Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Collection of peripheral blood progenitor cells for autografting with low-dose cyclophosphamide plus granulocyte colony-stimulating factor.
    Bellido M; Sureda A; Martino R; Madoz P; García J; Brunet S
    Haematologica; 1998 May; 83(5):428-31. PubMed ID: 9658727
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chemomobilization with Etoposide is Highly Effective in Patients with Multiple Myeloma and Overcomes the Effects of Age and Prior Therapy.
    Wood WA; Whitley J; Moore D; Sharf A; Irons R; Rao K; Serody J; Coghill J; Gabriel D; Shea T
    Biol Blood Marrow Transplant; 2011 Jan; 17(1):141-6. PubMed ID: 20637882
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prospective randomized clinical trial comparing high-dose ifosfamide + GM-CSF vs high-dose cyclophosphamide + GM-CSF for blood progenitor cell mobilization.
    Vela-Ojeda J; Tripp-Villanueva F; Montiel-Cervantes L; Sánchez-Cortés E; Ayala-Sánchez M; Guevara-Moreno ME; García-León LD; Rosas-Cabral A; Esparza MA; González-Llaven J
    Bone Marrow Transplant; 2000 Jun; 25(11):1141-6. PubMed ID: 10849526
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.
    Pusic I; Jiang SY; Landua S; Uy GL; Rettig MP; Cashen AF; Westervelt P; Vij R; Abboud CN; Stockerl-Goldstein KE; Sempek DS; Smith AL; DiPersio JF
    Biol Blood Marrow Transplant; 2008 Sep; 14(9):1045-1056. PubMed ID: 18721768
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Blood graft cellular composition and posttransplant outcomes in myeloma patients mobilized with or without low-dose cyclophosphamide: a randomized comparison.
    Valtola J; Silvennoinen R; Ropponen A; Siitonen T; Säily M; Sankelo M; Terävä V; Putkonen M; Kuittinen T; Pelkonen J; Mäntymaa P; Remes K; Varmavuo V; Jantunen E
    Transfusion; 2016 Jun; 56(6):1394-401. PubMed ID: 27041692
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7 g/m2) and granulocyte colony-stimulating factor in patients with multiple myeloma.
    Goldschmidt H; Hegenbart U; Haas R; Hunstein W
    Bone Marrow Transplant; 1996 May; 17(5):691-7. PubMed ID: 8733683
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Low-dose cyclophosphamide and granulocyte colony-stimulating factor are sufficient for peripheral blood stem cell mobilization in patients with multiple myeloma.
    Keklik M; Karakus E; Kaynar L; Akyol G; Guven ZT; Celik S; Baydar M; Sanlı N; Unal A; Cetin M
    Transfus Apher Sci; 2020 Oct; 59(5):102844. PubMed ID: 32586769
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma.
    Avigan ZM; Arinsburg S; Pan D; Mark T; Fausel C; Bubalo J; Milkovich G; Moshier E; Fu W; Chari A; Richter J
    Bone Marrow Transplant; 2024 Oct; 59(10):1440-1448. PubMed ID: 39085373
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effect of the dexamethasone, cytarabine, and cisplatin (DHAP) regimen on stem cell mobilization and transplant outcomes of patients with non-Hodgkin's lymphoma who are candidates for up-front autologous stem cell transplantation.
    Jeon SY; Yhim HY; Kim HS; Kim JA; Yang DH; Kwak JY
    Korean J Intern Med; 2018 Nov; 33(6):1169-1181. PubMed ID: 29295612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.